Augmedix, Inc. provided revenue guidance for the fourth quarter ended December 31, 2022. The company's revenue in the fourth quarter of 2022 is expected to be within the guidance range of $8.5 million to $8.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9265 USD | -2.48% |
|
+3.59% | -84.16% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.16% | 4.65Cr | |
+19.43% | 7.36TCr | |
+15.22% | 1.89TCr | |
+21.15% | 1.49TCr | |
+13.16% | 1.31TCr | |
+9.84% | 995.2Cr | |
-21.32% | 728.24Cr | |
-2.02% | 607.07Cr | |
+11.64% | 558.79Cr | |
+8.88% | 558.54Cr |
- Stock Market
- Equities
- AUGX Stock
- News Augmedix, Inc.
- Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022